ArticleAntimicrobial agents and chemotherapy2015
Molecular Analysis of the embCAB Locus and embR Gene Involved in Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis in France.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 68 citations in OpenAlex.
- A Type VII-secreted toxin enables inter-mycobacterial competition.Nature communications · 2026Article
- Genomic characterization of XDR Mycobacterium tuberculosis isolates in Argentina (2006-2015).BMC infectious diseases · 2025Article
- Resistance characteristics of culture-positive tuberculosis from 2015 to 2022.Frontiers in public health · 2025Article
- Mutations inAntibiotics (Basel, Switzerland) · 2024Article
- Genomic and phenotypic characterization ofMicrobiology spectrum · 2024Article
- Identification ofInfection and drug resistance · 2024Review
- The acetylation of pknH is linked to the ethambutol resistance of Mycobacterium tuberculosis.Archives of microbiology · 2023Article
- Molecular Analysis of Anti-Tuberculosis Drug Resistance ofAntibiotics (Basel, Switzerland) · 2023Article
- Identification of D-arabinan-degrading enzymes in mycobacteria.Nature communications · 2023Article
- The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives.Clinical microbiology reviews · 2022Review
- Article
- Characterization of Fluoroquinolone-Resistant and Multidrug-ResistantInfection and drug resistance · 2022Article
- Structure and Function of Mycobacterial Arabinofuranosyltransferases.Sub-cellular biochemistry · 2022Article
- Drug resistantPeerJ · 2022Article
- Computational prediction and validation of specific EmbR binding site on PknH.Synthetic and systems biotechnology · 2021Article
- A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TBFrontiers in cellular and infection microbiology · 2021Article
- Frequency of Codon 306 Mutations inInternational journal of preventive medicine · 2020Review
- Detecting Ethambutol Resistance inFrontiers in microbiology · 2020Article
- Exploiting Homoplasy in Genome-Wide Association Studies to Enhance Identification of Antibiotic-Resistance Mutations in Bacterial Genomes.Evolutionary bioinformatics online · 2020Article
- Drug-resistance inMedChemComm · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modification of codon 306 in embB is regarded as the main mechanism leading to ethambutol (ETB) resistance in clinical isolates of Mycobacterium tuberculosis. However, numerous mutations elsewhere in the embCAB locus and in embR, a putative transcriptional activator of this locus, have been reported to be involved in ETB resistance. Here, we investigated the diversity of nucleotide variations observed in embCAB and embR in M. tuberculosis complex isolates from France. These regions were sequenced in 71 ETB-resistant (ETB-R) and 60 ETB-susceptible (ETB-S) clinical isolates of known phylogenetic lineages. The 131 isolates had 12 mutations corresponding to phylogenetic markers. Among the 60 ETB-S isolates, only 3 (5%) had nonsynonymous mutations that were not phylogenetic markers. Among the 71 ETB-R isolates, 98% had mutations in embCAB that likely contribute to ETB resistance: 70% had mutations located in embB codon 306, 406, or 497; 13% had mutations located outside these three positions between codons 296 and 426; and 15% had mutations corresponding to mutations in the embC-embA intergenic region. We found a strong association between resistance to ETB and the presence of mutations in embB and the embC-embA intergenic region (P < 0.001). In contrast, the mutations detected in embC and embA were not involved in ETB resistance, and no mutation was detected in embR. These results strongly suggest that the sensitivity of diagnostic assays for detecting ETB resistance based on testing of embB codon 306 can be increased by testing of the embB region between codons 296 and 497 and by including the embC-embA intergenic region between positions -8 and -21.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.